Results
Title

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.

Authors

Namba, Mitsuyoshi; Katsuno, Tomoyuki; Kusunoki, Yoshiki; Matsuo, Toshihiro; Miuchi, Masayuki; Miyagawa, Jun-ichiro

Abstract

Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted mainly through the hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted from L cells localized in the small intestine. The benefits of this therapy over conventional sulfonylureas or insulin injections, such as fewer hypoglycemic events and reduced body weight gain, derive from the glucose-dependent insulinotropic effect. The protective effects of this therapy on vulnerable pancreatic β-cells and against micro/macroangiopathy in T2DM are also most welcome. Indications and/or contraindications for incretin-based therapy should be clarified by prospectively studying the experiences of Japanese T2DM patients undergoing this therapy in the clinical setting.

Subjects

UNITED States; TYPE 2 diabetes treatment; INCRETINS; GLUCAGON-like peptide-1 receptor; SULFONYLUREAS; BODY weight; PANCREATIC beta cells

Publication

Clinical & Experimental Nephrology, 2013, Vol 17, Issue 1, p10

ISSN

1342-1751

Publication type

Academic Journal

DOI

10.1007/s10157-012-0709-0